Switch theme
Sign up to access all valuation multiples
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
2006
181
LTM Revenue $519M
LTM EBITDA $241M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Catalyst Pharmaceuticals has a last 12-month revenue (LTM) of $519M and a last 12-month EBITDA of $241M.
In the most recent fiscal year, Catalyst Pharmaceuticals achieved revenue of $492M and an EBITDA of $233M.
Catalyst Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Catalyst Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $519M | XXX | $492M | XXX | XXX | XXX |
| Gross Profit | $443M | XXX | $423M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $241M | XXX | $233M | XXX | XXX | XXX |
| EBITDA Margin | 46% | XXX | 47% | XXX | XXX | XXX |
| EBIT | $211M | XXX | $195M | XXX | XXX | XXX |
| EBIT Margin | 41% | XXX | 40% | XXX | XXX | XXX |
| Net Profit | $178M | XXX | $164M | XXX | XXX | XXX |
| Net Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Catalyst Pharmaceuticals's stock price is $25.
Catalyst Pharmaceuticals has current market cap of $3.0B, and EV of $2.5B.
See Catalyst Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $3.0B | XXX | XXX | XXX | XXX | $1.41 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Catalyst Pharmaceuticals has market cap of $3.0B and EV of $2.5B.
Catalyst Pharmaceuticals's trades at 5.0x EV/Revenue multiple, and 10.6x EV/EBITDA.
Equity research analysts estimate Catalyst Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Catalyst Pharmaceuticals has a P/E ratio of 17.1x.
See valuation multiples for Catalyst Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | 10.3x | XXX | 10.6x | XXX | XXX | XXX |
| EV/EBIT | 11.7x | XXX | 12.6x | XXX | XXX | XXX |
| EV/Gross Profit | 5.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.1x | XXX | 18.6x | XXX | XXX | XXX |
| EV/FCF | 10.2x | XXX | 10.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCatalyst Pharmaceuticals's last 12 month revenue growth is 13%
Catalyst Pharmaceuticals's revenue per employee in the last FY averaged $2.7M, while opex per employee averaged $1.3M for the same period.
Catalyst Pharmaceuticals's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Catalyst Pharmaceuticals's rule of X is 78% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Catalyst Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 46% | XXX | 47% | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | 35% | XXX | XXX | XXX |
| Rule of 40 | 43% | XXX | 60% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 78% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Catalyst Pharmaceuticals acquired XXX companies to date.
Last acquisition by Catalyst Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Catalyst Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Catalyst Pharmaceuticals founded? | Catalyst Pharmaceuticals was founded in 2006. |
| Where is Catalyst Pharmaceuticals headquartered? | Catalyst Pharmaceuticals is headquartered in United States of America. |
| How many employees does Catalyst Pharmaceuticals have? | As of today, Catalyst Pharmaceuticals has 181 employees. |
| Who is the CEO of Catalyst Pharmaceuticals? | Catalyst Pharmaceuticals's CEO is Mr. Richard J. Daly. |
| Is Catalyst Pharmaceuticals publicy listed? | Yes, Catalyst Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Catalyst Pharmaceuticals? | Catalyst Pharmaceuticals trades under CPRX ticker. |
| When did Catalyst Pharmaceuticals go public? | Catalyst Pharmaceuticals went public in 2006. |
| Who are competitors of Catalyst Pharmaceuticals? | Similar companies to Catalyst Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Catalyst Pharmaceuticals? | Catalyst Pharmaceuticals's current market cap is $3.0B |
| What is the current revenue of Catalyst Pharmaceuticals? | Catalyst Pharmaceuticals's last 12 months revenue is $519M. |
| What is the current revenue growth of Catalyst Pharmaceuticals? | Catalyst Pharmaceuticals revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Catalyst Pharmaceuticals? | Current revenue multiple of Catalyst Pharmaceuticals is 4.8x. |
| Is Catalyst Pharmaceuticals profitable? | Yes, Catalyst Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Catalyst Pharmaceuticals? | Catalyst Pharmaceuticals's last 12 months EBITDA is $241M. |
| What is Catalyst Pharmaceuticals's EBITDA margin? | Catalyst Pharmaceuticals's last 12 months EBITDA margin is 46%. |
| What is the current EV/EBITDA multiple of Catalyst Pharmaceuticals? | Current EBITDA multiple of Catalyst Pharmaceuticals is 10.3x. |
| What is the current FCF of Catalyst Pharmaceuticals? | Catalyst Pharmaceuticals's last 12 months FCF is $241M. |
| What is Catalyst Pharmaceuticals's FCF margin? | Catalyst Pharmaceuticals's last 12 months FCF margin is 46%. |
| What is the current EV/FCF multiple of Catalyst Pharmaceuticals? | Current FCF multiple of Catalyst Pharmaceuticals is 10.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
